Klaudia Kalmárová, Vladimír Nosáľ, Juraj Sokol, Ingrid Škorňová, Egon Kurča
Recurrent stroke represents a quarter of all strokes and occurs often due to failure of secondary prevention. The most
common cause of ischemic stroke is thrombotic and embolic complications of atherosclerosis. Antiplatelet drugs play
a major rolein secondary prevention of ischemic stroke. Up to 25% of patients receiving long-term aspirin was detected
to have incomplete inhibition of platelet aggregation, and up to 35% of patients with good initial effect of ASA develop
with prolonged use aspirin resistance. Resistance occurs in clopidogrel also. We provide an overview of the principles
of platelet aggregation, the antiplatelet agents, we discuss the issue of aspirin and clopidogrel resistance, and
provide an overview of the current available methods for monitoring the antiplatelet therapy.